October 2023 tender notification
Te Pātaka Whaioranga - Pharmac is pleased to provide the latest tender results
Download the tender notification [PDF 49 KB]
Tender results
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2022/23 Invitation to Tender, dated 31 October 2022.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 November 2023 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2021/22 Tender – Principal Supply Status applies until 30 June 2025
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
1. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Nicorandil1 |
Tab 10 mg; 60 tablet blister pack |
$25.57 |
$21.73 |
Max Health (Max Health) |
1 December 2023 |
1 May 2024 |
Ikorel (Sanofi-AU) |
|
Nicorandil1 |
Tab 20 mg; 60 tablet blister pack |
$32.28 |
$27.44 |
Max Health (Max Health) |
1 December 2023 |
1 May 2024 |
Ikorel (Sanofi-AU) |
|
1Brand switch fee of $4.50 is payable for this product from 1 May 2024 to 31 July 2024 |
|||||||
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
The decisions were as follows (deletions to presentation in strikethrough, additions in bold):
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
DV |
Date of price change |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|---|
|
Nicorandil |
Tab 10 mg; 60 tablet blister pack |
$25.57 |
$21.73 |
Max Health (Max Health) |
5% |
1 December 2023 |
1 May 2024 |
Ikorel (Sanofi-AU) |
|
|
Nicorandil |
Tab 20 mg; 60 tablet blister pack |
$32.28 |
$27.44 |
Max Health (Max Health) |
5% |
1 December 2023 |
1 May 2024 |
Ikorel (Sanofi-AU) |
|
|
Nimodipine
|
Inj 200 mcg 0.2 mcg per ml, 50 ml vial; 5 vial pack |
$337.50 |
$337.50 |
Nimotop (Pharmacode 2663937) (Bayer) |
5% |
1 December 2023 |
1 May 2024 |
Nimotop (Pharmacode 818453) (Bayer) |
|
2022/23 Tender – Principal Supply Status applies until 30 June 2026
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
3. Tenders awarded to pharmaceuticals where no other brand is listed.
|
Chemical name |
Presentation; |
Pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
|---|---|---|---|---|---|---|
|
Ephedrine |
Inj 3 mg per ml, 10 ml syringe; 10 syringe pack |
$142.00 |
Ephedrine Juno (Juno) |
5% |
1 January 2024 |
1 June 2024 |
Tender declines - Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the:
- 2021/22 Invitation to Tender, dated 1 November 2021
- 2022/23 Invitation to Tender dated 31 October 2022
2021/22 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Acetazolamide |
Tab 250 mg |
|
Amisulpride |
Tab 100 mg |
|
Amisulpride |
Tab 200 mg |
|
Amisulpride |
Tab 400 mg |
|
Amoxicillin with clavulanic acid |
Grans for oral liq 125 mg with potassium clavulante 31.25 mg per 5 ml |
|
Amoxicillin with clavulanic acid |
Grans for oral liq 250 mg with potassium clavulante 62.5 mg per 5 ml |
|
Cetomacrogol with glycerol |
Crm 90% with glycerol 10%, 100 g |
|
Ertapenem |
Inj 1 g vial |
|
Haloperidol |
Inj 5 mg per ml, 1 ml |
|
Levosimendan |
Inj 2.5 mg per ml, 5 ml |
|
Medroxyprogesterone |
Inj long-acting 150 mg per ml, 1 ml syringe |
|
Pemetrexed |
Inj 100 mg |
|
Pemetrexed |
Inj 500 mg |
|
Sodium hyaluronate [hyaluronic acid] |
Inj 30 mg per ml |
|
Tenecteplase |
Inj 50 mg |
|
Tranylcypromine sulphate |
Tab 10 mg |
2022/23 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Fosfomycin (current access) |
Powder |
|
Fosfomycin (widened access) |
Powder |
|
Hyoscine N-butylbromide |
Tab 10 mg |
|
Metaraminol tartrate |
Inj 0.5 mg per ml, 10 ml |
|
Metaraminol tartrate |
Inj 0.5 mg per ml, 5 ml |
|
Noradrenaline |
Inj 0.06 mg per ml, 50 ml syringe |
|
Noradrenaline |
Inj 0.1 mg per ml, 50 ml syringe |
For products included in the 2021/22 and 2022/2023 Invitation to Tender where no announcement has yet been made, either a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.